Market Summary
USD206.39-0.60
Market Closed-0.29%
SGEN Stock Price
SGEN RSI Chart
SGEN Valuation
SGEN Price/Sales (Trailing)
SGEN Profitability
SGEN Fundamentals
SGEN Revenue
SGEN Earnings
Price Action
52 Week Range
210.50
(Low)(High)
Last 7 days
0.5%
Last 30 days
7.1%
Last 90 days
4.1%
Trailing 12 Months
45.8%
SGEN Financial Health
SGEN Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for SGEN
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-07 | HIMES VAUGHN B | sold | -1,807,600 | 205 | -8,785 | chief technical officer |
2023-09-07 | HIMES VAUGHN B | acquired | 387,331 | 44.09 | 8,785 | chief technical officer |
2023-08-31 | LIU JEAN I | sold | -391,786 | 206 | -1,893 | chief legal officer |
2023-08-31 | DANSEY ROGER D | sold | -833,866 | 206 | -4,029 | president, r&d & cmo |
2023-08-31 | HIMES VAUGHN B | sold | -371,504 | 206 | -1,795 | chief technical officer |
2023-08-31 | ROMP CHARLES R | sold | -114,866 | 206 | -555 | evp, commercial u.s. |
2023-08-31 | SIMPSON TODD E | sold | -439,182 | 206 | -2,122 | chief financial officer |
2023-08-29 | HIMES VAUGHN B | sold | -76,426 | 206 | -371 | chief technical officer |
2023-08-29 | ROMP CHARLES R | sold | -90,228 | 206 | -438 | evp, commercial u.s. |
2023-08-29 | LIU JEAN I | sold | -83,430 | 206 | -405 | chief legal officer |
Which funds bought or sold SGEN recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-12 | Farther Finance Advisors, LLC | added | 10.45 | 677 | 14,242 | -% |
2023-08-29 | Garde Capital, Inc. | unchanged | - | -15,000 | 279,000 | 0.02% |
2023-08-29 | EFG Asset Management (Americas) Corp. | sold off | -100 | -4,050,620 | - | -% |
2023-08-25 | Yarbrough Capital, LLC | unchanged | - | -45,305 | 871,074 | 0.05% |
2023-08-24 | Alberta Investment Management Corp | added | 520 | 3,372,510 | 4,060,910 | 0.04% |
2023-08-23 | CTC Alternative Strategies, Ltd. | new | - | 371,063 | 371,063 | 0.46% |
2023-08-22 | COMERICA BANK | new | - | 2,000 | 2,000 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -7.68 | -1,361,900 | 9,660,940 | 0.02% |
2023-08-21 | BOKF, NA | sold off | -100 | -810 | - | -% |
2023-08-21 | Affinity Asset Advisors, LLC | sold off | -100 | -4,049,400 | - | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Seagen
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jun 09, 2023 | capital international investors | 3.9% | 7,227,865 | SC 13G/A | |
| May 03, 2023 | baker bros. advisors lp | 23.8% | 44,617,299 | SC 13D/A | |
| Mar 13, 2023 | baker bros. advisors lp | 25.1% | 46,985,656 | SC 13D/A | |
| Feb 13, 2023 | capital international investors | 9.7% | 18,058,081 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 6.97% | 12,945,078 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 5.32% | 9,881,292 | SC 13G/A | |
| Feb 01, 2023 | blackrock inc. | 6.4% | 11,861,464 | SC 13G/A | |
| Mar 10, 2022 | baker bros. advisors lp | 25.6% | 46,975,613 | SC 13D/A | |
| Feb 11, 2022 | capital international investors | 7.0% | 12,778,429 | SC 13G/A | |
| Feb 04, 2022 | wellington management group llp | 6.36% | 11,629,729 | SC 13G |
Recent SEC filings of Seagen
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 08, 2023 | 4 | Insider Trading | |
| Sep 07, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 05, 2023 | 8-K | Current Report | |
| Sep 01, 2023 | 4 | Insider Trading | |
| Sep 01, 2023 | 4 | Insider Trading | |
| Sep 01, 2023 | 4 | Insider Trading | |
| Sep 01, 2023 | 4 | Insider Trading | |
| Sep 01, 2023 | 4 | Insider Trading | |
| Aug 31, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 31, 2023 | 144 | Notice of Insider Sale Intent |
Peers (Alternatives to Seagen)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 145.2B | 26.6B | 4.13% | 21.09% | 18.2 | 5.46 | 0.75% | 21.34% |
GILD | 94.5B | 27.4B | -0.16% | 19.51% | 17.24 | 3.45 | -0.48% | 32.56% |
MRNA | 39.4B | 10.7B | -6.80% | -20.18% | 32.68 | 3.7 | -53.67% | -91.41% |
BIIB | 37.7B | 10.0B | -1.71% | 27.59% | 14.15 | 3.78 | -6.23% | 29.40% |
| MID-CAP | ||||||||
NBIX | 11.2B | 1.7B | 5.59% | 6.81% | 63.29 | 6.67 | 29.01% | 1345.90% |
BBIO | 4.5B | - | -3.04% | 140.92% | -7.66 | 48.33 | 54.84% | -12.96% |
DNLI | 3.1B | - | -4.51% | -22.98% | -23.78 | 37.44 | 122.90% | 54.78% |
BEAM | 2.0B | 80.2M | 6.46% | -52.82% | -6.01 | 24.54 | 42.17% | -39.82% |
| SMALL-CAP | ||||||||
RCUS | 1.5B | 121.2M | 4.38% | -25.42% | -5.13 | 12.17 | -70.36% | -531.73% |
REPL | 980.2M | 15.3M | -15.63% | 3.04% | -5.4 | 64.02 | 1090.59% | -36.57% |
NVAX | 664.9M | 1.6B | -12.64% | -74.33% | -1.13 | 0.42 | 23.74% | 60.24% |
FATE | 221.7M | - | -17.58% | -90.72% | -1.05 | 1.62 | 116.83% | 16.61% |
SGMO | 146.7M | - | -8.84% | -84.12% | -0.74 | 0.61 | 113.96% | -15.19% |
VXRT | 112.7M | 2.1M | -6.14% | -67.90% | -1.12 | 54.83 | 487.70% | -8.66% |
IBIO | 4.1M | - | -12.28% | -96.10% | -0.05 | 3.21 | - | -129.46% |
Seagen News
Returns for SGEN
Cumulative Returns on SGEN
16.2%
10-Year Cumulative Returns
20.5%
7-Year Cumulative Returns
21.6%
5-Year Cumulative Returns
4.6%
3-Year Cumulative Returns
Risks for SGEN
What is the probability of a big loss on SGEN?
71.2%
Probability that Seagen stock will be more than 20% underwater in next one year
60.8%
Probability that Seagen stock will be more than 30% underwater in next one year.
0%
Probability that Seagen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does SGEN drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Seagen was unfortunately bought at previous high price.
Drawdowns
Financials for Seagen
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 5.2% | 2,162,001,000 | 2,055,671,000 | 1,962,412,000 | 1,864,113,000 | 1,777,873,000 | 1,668,849,000 | 1,574,371,000 | 1,745,814,000 | 2,383,485,000 | 2,273,005,000 | 2,175,536,000 | 1,864,047,000 | 1,015,579,000 | 956,028,000 | 916,713,000 | 801,422,000 | 757,583,000 | 709,309,000 | 654,700,000 | 609,792,000 | 575,659,000 |
| Costs and Expenses | 7.1% | 2,914,044,000 | 2,720,104,000 | 2,575,382,000 | 2,495,149,000 | 2,514,067,000 | 2,361,535,000 | 2,256,427,000 | 2,090,814,000 | 1,792,336,000 | 1,686,218,000 | 1,578,684,000 | 1,470,595,000 | 1,350,097,000 | 1,235,291,000 | 1,137,258,000 | 1,073,864,000 | 985,815,000 | 929,115,000 | 914,698,000 | 824,491,000 | 776,981,000 |
| S&GA Expenses | 2.7% | 906,852,000 | 883,179,000 | 820,963,000 | 815,799,000 | 785,702,000 | 730,573,000 | 716,190,000 | 663,618,000 | 610,916,000 | 571,428,000 | 533,835,000 | 490,699,000 | 459,221,000 | 415,910,000 | 373,932,000 | 338,170,000 | 299,224,000 | 275,185,000 | 261,096,000 | 230,079,000 | 212,591,000 |
| R&D Expenses | 6.8% | 1,498,331,000 | 1,402,717,000 | 1,344,361,000 | 1,290,812,000 | 1,365,299,000 | 1,295,906,000 | 1,228,672,000 | 1,140,563,000 | 899,141,000 | 862,357,000 | 827,129,000 | 812,007,000 | 790,456,000 | 756,308,000 | 719,374,000 | 668,085,000 | 612,141,000 | 571,072,000 | 565,309,000 | 526,041,000 | 499,472,000 |
| EBITDA | 100.0% | - | -589,440,000 | -555,588,000 | -588,369,000 | -693,551,000 | -644,806,000 | -632,805,000 | -292,662,000 | 638,329,000 | 651,701,000 | 651,701,000 | 1,354,159,000 | -134,969,000 | -134,969,000 | -134,850,000 | - | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -0.29 | -0.28 | -0.32 | -0.39 | -0.39 | -0.40 | -0.17 | 0.27 | 0.29 | 0.30 | 0.73 | -0.13 | -0.14 | -0.15 | - | - | - | - | - | - |
| Earnings Before Taxes | -11.6% | -711,105,000 | -637,188,000 | -602,315,000 | -635,461,000 | -739,669,000 | -689,525,000 | -675,705,000 | -332,847,000 | 599,297,000 | 911,830,667 | 615,701,000 | 1,330,478,000 | - | - | -158,650,000 | -367,652,000 | - | - | -246,346,000 | - | - |
| EBT Margin | 100.0% | - | -0.31 | -0.31 | -0.34 | -0.42 | -0.41 | -0.43 | -0.19 | 0.25 | 0.27 | 0.28 | 0.71 | -0.16 | -0.17 | -0.17 | - | - | - | - | - | - |
| Net Income | -11.8% | -725,252,000 | -648,551,000 | -610,308,000 | -636,765,000 | -739,796,000 | -689,545,000 | -674,471,000 | -332,748,000 | 597,266,000 | 660,652,000 | 613,670,000 | 472,405,000 | -255,675,000 | -313,723,000 | -158,650,000 | -304,285,000 | -279,818,000 | -124,307,000 | -222,693,000 | -162,089,000 | -44,622,000 |
| Net Income Margin | 100.0% | - | -0.32 | -0.31 | -0.34 | -0.42 | -0.41 | -0.43 | -0.19 | 0.25 | 0.29 | 0.28 | 0.25 | -0.25 | -0.33 | -0.17 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -585,180,000 | -531,091,000 | -719,364,000 | -651,907,000 | -652,705,000 | -551,337,000 | -81,745,000 | 756,475,000 | 735,633,000 | 774,159,000 | 570,684,000 | -312,408,000 | -259,044,000 | -234,490,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -1.4% | 3,495 | 3,543 | 3,675 | 3,619 | 3,630 | 3,617 | 3,720 | 3,978 | 3,952 | 3,943 | 4,001 | 3,005 | 2,165 | 2,091 | 2,206 | 2,098 | 1,568 | 1,593 | 1,503 | 1,568 | 1,581 |
| Current Assets | -3.3% | 2,516 | 2,602 | 2,803 | 2,760 | 2,779 | 2,771 | 2,869 | 3,115 | 3,099 | 3,104 | 3,062 | 2,166 | 1,331 | 1,160 | 1,177 | 1,196 | 672 | 680 | 654 | 717 | 706 |
| Cash Equivalents | -8.2% | 308 | 336 | 320 | 363 | 375 | 261 | 425 | 685 | 413 | 374 | 558 | 919 | 117 | 249 | 275 | 193 | 64.00 | 84.00 | 78.00 | 115 | 159 |
| Inventory | 1.9% | 487 | 478 | 427 | 365 | 319 | 276 | 201 | 181 | 163 | 147 | 116 | 97.00 | 90.00 | 85.00 | 86.00 | 92.00 | 73.00 | 67.00 | 53.00 | 75.00 | 71.00 |
| Net PPE | 16.5% | 308 | 264 | 248 | 230 | 219 | 214 | 210 | 209 | 203 | 197 | 197 | 193 | 185 | 175 | 155 | 145 | 131 | 115 | 104 | 101 | 101 |
| Goodwill | 0% | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 251 | 251 |
| Current Liabilities | 7.0% | 763 | 713 | 818 | 726 | 609 | 531 | 569 | 698 | 434 | 390 | 388 | 593 | 283 | 257 | 259 | 246 | 222 | 208 | 225 | 194 | 181 |
| Shareholder's Equity | -3.8% | 2,619 | 2,723 | 2,804 | 2,822 | 2,933 | 2,998 | 3,065 | 3,165 | 3,391 | 3,425 | 3,488 | 2,258 | 1,814 | 1,766 | 1,876 | 1,780 | 1,272 | 1,313 | 1,274 | 1,365 | 1,382 |
| Retained Earnings | -9.1% | -2,540 | -2,329 | -2,154 | -2,006 | -1,815 | -1,680 | -1,544 | -1,369 | -1,075 | -990 | -869 | -1,036 | -1,672 | -1,651 | -1,483 | -1,509 | -1,417 | -1,337 | -1,324 | -1,204 | -1,137 |
| Additional Paid-In Capital | 2.1% | 5,155 | 5,048 | 4,954 | 4,825 | 4,747 | 4,678 | 4,608 | 4,533 | 4,466 | 4,415 | 4,357 | 3,294 | 3,485 | 3,414 | 3,359 | 3,288 | 2,688 | 2,651 | 2,598 | 2,569 | 2,520 |
| Shares Outstanding | 0.2% | 188 | 187 | 187 | 185 | 184 | 184 | 183 | 182 | 182 | 181 | 181 | 174 | 173 | 172 | 172 | 168 | 161 | 161 | 160 | 159 | 158 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -21.3% | -590 | -486 | -453 | -657 | -589 | -590 | -499 | -26.48 | 814 | 800 | 857 | 656 | -227 | -175 | -163 | -176 | -126 | -113 | -203 | -181 | -178 |
| Share Based Compensation | 16.2% | 280 | 241 | 221 | 209 | 195 | 179 | 173 | 161 | 155 | 152 | 147 | 155 | 144 | 135 | 127 | 105 | 98.00 | 88.00 | 79.00 | 69.00 | 64.00 |
| Cashflow From Investing | -9.2% | 394 | 434 | 228 | 266 | 469 | 394 | 289 | -1,035 | -1,343 | -1,519 | -1,419 | -30.29 | -371 | -292 | -277 | -359 | -38.70 | -59.18 | -592 | -556 | -566 |
| Cashflow From Financing | -0.9% | 127 | 129 | 125 | 82.00 | 86.00 | 85.00 | 78.00 | 829 | 826 | 844 | 846 | 101 | 653 | 633 | 638 | 613 | 70.00 | 70.00 | 713 | 725 | 707 |
SGEN Income Statement
2023-06-30Condensed Consolidated Statements of Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues: | ||||
| Total revenues | $ 603,832 | $ 497,502 | $ 1,123,551 | $ 923,962 |
| Costs and expenses: | ||||
| Cost of sales | 180,753 | 106,100 | 292,529 | 193,726 |
| Research and development | 399,868 | 304,254 | 755,883 | 601,913 |
| Selling, general and administrative | 243,932 | 220,259 | 480,373 | 394,484 |
| Total costs and expenses | 824,553 | 630,613 | 1,528,785 | 1,190,123 |
| Loss from operations | (220,721) | (133,111) | (405,234) | (266,161) |
| Investment and other income (loss), net | 12,084 | (1,609) | 26,484 | (3,799) |
| Loss before income taxes | (208,637) | (134,720) | (378,750) | (269,960) |
| Provision for income taxes | 2,891 | 107 | 7,515 | 1,361 |
| Net loss | $ (211,528) | $ (134,827) | $ (386,265) | $ (271,321) |
| Net loss per share - basic (in dollars per share) | $ (1.13) | $ (0.73) | $ (2.06) | $ (1.48) |
| Net loss per share - diluted (in dollars per share) | $ (1.13) | $ (0.73) | $ (2.06) | $ (1.48) |
| Shares used in computation of per share amounts - basic (in shares) | 187,559 | 184,145 | 187,226 | 183,897 |
| Shares used in computation of per share amounts - diluted (in shares) | 187,559 | 184,145 | 187,226 | 183,897 |
| Comprehensive loss: | ||||
| Net loss | $ (211,528) | $ (134,827) | $ (386,265) | $ (271,321) |
| Other comprehensive income (loss): | ||||
| Unrealized gain (loss) on securities available-for-sale, net of tax | 172 | (2,736) | 1,542 | (3,597) |
| Foreign currency translation gain (loss) | 228 | 2,819 | (944) | 2,925 |
| Total other comprehensive income (loss) | 400 | 83 | 598 | (672) |
| Comprehensive loss | (211,128) | (134,744) | (385,667) | (271,993) |
| Net product sales | ||||
| Revenues: | ||||
| Total revenues | 543,974 | 431,714 | 1,012,613 | 814,800 |
| Royalty revenues | ||||
| Revenues: | ||||
| Total revenues | 51,189 | 39,109 | 81,367 | 67,290 |
| Collaboration and license agreement revenues | ||||
| Revenues: | ||||
| Total revenues | $ 8,669 | $ 26,679 | $ 29,571 | $ 41,872 |
SGEN Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 308,441 | $ 319,940 |
| Short-term investments | 983,678 | 1,415,130 |
| Accounts receivable, net | 586,048 | 501,912 |
| Inventories | 486,854 | 427,211 |
| Prepaid expenses and other current assets | 150,675 | 138,340 |
| Total current assets | 2,515,696 | 2,802,533 |
| Property and equipment, net | 307,518 | 248,179 |
| Operating lease right-of-use assets | 120,628 | 46,738 |
| Intangible assets, net | 226,072 | 237,516 |
| Goodwill | 274,671 | 274,671 |
| Other non-current assets | 50,797 | 64,895 |
| Total assets | 3,495,382 | 3,674,532 |
| Current liabilities: | ||
| Accounts payable | 114,415 | 207,851 |
| Accrued liabilities and other | 648,483 | 610,553 |
| Total current liabilities | 762,898 | 818,404 |
| Long-term liabilities: | ||
| Operating lease liabilities, long-term | 97,242 | 43,474 |
| Other long-term liabilities | 16,183 | 8,835 |
| Total long-term liabilities | 113,425 | 52,309 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 5,000 shares authorized; none issued | 0 | 0 |
| Common stock, $0.001 par value, 250,000 shares authorized; 187,672 shares issued and outstanding at June 30, 2023 and 186,559 shares issued and outstanding at December 31, 2022 | 188 | 187 |
| Additional paid-in capital | 5,155,375 | 4,954,469 |
| Accumulated other comprehensive income | 4,108 | 3,510 |
| Accumulated deficit | (2,540,612) | (2,154,347) |
| Total stockholders’ equity | 2,619,059 | 2,803,819 |
| Total liabilities and stockholders’ equity | $ 3,495,382 | $ 3,674,532 |
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.